Work

Final results from a phase 1/2, 48-month, open-label extension study of givosiran in patients with acute intermittent porphyria

Year: 2023

Type: article

Source: Journal of Hepatology

DOI: 10.1016/s0168-8278(23)00575-5

Authors: Eliane Sardh, Manisha Balwani, David Rees, Karl Anderson, Gang Jia, Marianne T Sweetser, Bruce Wang

Language: English

Topic: Porphyrin Metabolism and Disorders

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4384946423

FWCI:

Cites:

Cited by:

Related to: 10